Speaker illustration

Doctor Hugh Calkins

The Johns Hopkins Hospital, Baltimore (United States of America)

Member of:

European Society of Cardiology

Uninterrupted NOACs in atrial fibrillation ablation: what have we learned from the clinical trials?

Event: ESC Congress 2018

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Should we perform atrial fibrillation ablation in asymptomatic patients?

Event: ESC Congress 2018

Topic: Atrial Fibrillation (AF)

Session type: Debate Session

Thumbnail

Complex decisions in atrial fibrillation ablation

Event: EHRA 2018

Topic: Rhythm Control, Catheter Ablation

Session type: Meet the Experts

Thumbnail

The future of cardiac mapping and ablation

Event: EHRA 2018

Topic: Arrhythmias, General – Diagnostic Methods

Session type: Symposium

Thumbnail

Rewire your thinking on AF ablation: impact of uninterrupted dabigatran

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Breakthroughs in AF: from RE-CIRCUIT to reversal

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Atrial fibrillation ablation update, joint document with HRS

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Documents, Guidelines & Highlights

Session type: New ESC Guidelines

Thumbnail

The multiple facets of arrythmogenic ventricular cardiomyopathy

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Molecular biology / genetics

Session type: Symposium

Thumbnail

A specific reversal agent for dabigatran is available: should you have it in your electrophysiology lab?

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

State-of-the-art: Atrial Fibrillation (AF) ablation in patients on NOACs

Event: ESC CONGRESS 2015

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

This platform is supported by

logo Novo Nordisk